Scott Keating
About Scott Keating
Scott Keating is the Associate Director of US Health Economics & Outcomes Research for CAR-T at Bristol Myers Squibb, with extensive experience in health-economic analyses and CAR-T therapies.
Current Title and Company
Scott Keating is currently serving as the Associate Director of US Health Economics & Outcomes Research, CAR-T at Bristol Myers Squibb. In this role, he is involved in strategic data generation and execution of health-economic analyses for CAR-T therapies.
Career at Bristol Myers Squibb
Scott Keating has held several key positions at Bristol Myers Squibb within the Health Economics & Outcomes Research (HEOR) sector. His roles have included Senior Manager and Manager of US HEOR for CAR-T therapies and Hematology-Oncology. Notably, he independently led the launch of two CAR-T indications in lymphoma and developed critical HEOR data generation strategies. During his tenure, he has been involved in matching-adjusted indirect comparisons (MAIC), cost-effectiveness analyses, and systematic literature reviews.
Previous Experience
Before his current role, Scott Keating gained experience at Bayer Pharmaceuticals as an intern in US Health Economics & Outcomes Research. His early career also includes a Research Aide position at Weill Cornell Medicine, where he contributed for two years.
Education and Expertise
Scott Keating holds a Master's degree in Health Policy and Economics from Weill Cornell Graduate School of Medical Sciences, achieved between 2016 and 2018. He also earned a Bachelor of Science in Biochemistry and Molecular Biology from the University of Massachusetts Amherst, where he studied from 2012 to 2016. His educational background has provided a strong foundation for his expertise in health-economic analyses, particularly in hematologic malignancies and chronic diseases.
Specialized Skills and Analysis
Scott Keating has led a variety of health-economic analyses, including retrospective observational studies, comparative effectiveness analyses, safety analyses, and healthcare resource utilization analyses. His therapeutic area experience includes hematologic malignancies such as leukemia, lymphoma, and multiple myeloma, along with some work in chronic diseases like diabetes. His skills extend to developing cost-effectiveness models and budget impact modeling, as well as conducting systematic literature reviews for regulatory submissions.